Intra-Cellular Therapies, Inc. (ITCI)

Market Cap	7.09B
Revenue (ttm)	464.37M
Net Income (ttm)	-139.67M
Shares Out	96.81M
EPS (ttm)	-1.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	567,254
Open	72.27
Previous Close	72.13
Day's Range	71.66 - 73.52
52-Week Range	45.50 - 84.89
Beta	1.02
Analysts	Strong Buy
Price Target	90.33 (+23.3%)
Earnings Date	May 10, 2024

About ITCI

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of vario...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: Dr. Sharon Mates Ph.D.
• Employees: 610
• Stock Exchange: NASDAQ
• Ticker Symbol: ITCI

Financial Performance

In 2023, ITCI's revenue was $464.37 million, an increase of 85.51% compared to the previous year's $250.31 million. Losses were -$139.67 million, -45.49% less than in 2022.

Analyst Forecast

According to 12 analysts, the average rating for ITCI stock is "Strong Buy." The 12-month stock price forecast is $90.33, which is an increase of 23.30% from the latest price.

Price Target

$90.33

(23.30% upside)

Analyst Consensus: Strong Buy